Gingivitis Clinical Trial
Official title:
21 Day Clinical Efficacy of Essential Oil Containing Mouth Rinses: Effect on Reducing Existing Gingivitis and Plaque
The reduction of existing plaque and gum inflammation will be evaluated using two marketed
mouth rinses along with tooth brushing after 21 days of use compared to a placebo mouth
rinse.
165 healthy volunteers will be enrolled in this three week study. Volunteers who qualify to
be in this study will have an equal chance of being assigned to one of the three treatment
groups. Volunteers will have a total of three visits including 1) Screening/Baseline Day 1
2) Day 11 (after 10 days of use) and 3) Day 22 (after 21 days of use). Volunteers will
maintain a diary at home to record each treatment use and will be asked to come to the
clinic without brushing or use their product for at least 8 hours, but no more than 18
hours. Examinations for oral hard/soft tissue, gingivitis, bleeding and plaque assessments
will be completed at Screening/Baseline and repeated at Clinic Visit 3, which is Day 22.
A sufficient number of generally healthy subjects (approximately 165) that meet the required
inclusion/exclusion criteria will be enrolled in this 21 day, examiner-blind, single center,
randomized, parallel-group controlled clinical trial to ensure that at least 150 subjects
(50 per treatment group) complete this study.
At baseline, the prescreened subjects will present to the clinic site for baseline
examinations (oral tissue assessment, gingivitis, bleeding and plaque assessments) having
refrained from oral hygiene for at least 8 hours, but no more than 18 hours. After the
baseline oral examinations, assessment of other inclusion/exclusion criteria qualifying
subjects will be randomly assigned to one of three treatment groups. Immediately following
this randomization, subjects will begin use of their assigned test product following the
label instructions. If randomized to the control group, subjects will brush twice daily in
their usual manner with an ADA accepted fluoride toothpaste and a soft bristled toothbrush
followed by rinsing twice daily with a 5% hydroalcohol control rinse (W002194-221P). If
randomized to an active treatment group; subjects will brush twice daily in their usual
manner, followed by rinsing twice daily with their assigned mouth rinse formulation
(19292-116A or 11965-059). Subjects will be instructed to follow label instructions 20ml for
30 seconds twice daily for mouth rinse product. The first product use will be conducted
under the supervision of study personnel. All other brushing and rinsing will be
unsupervised and the subjects will be required to maintain a diary card to document twice
daily product use, brushing and rinsing times. Compliance will be evaluated by weighing
residual volumes of returned mouth rinse and by reviewing the subject diary. Subjects will
receive an ADA- accepted fluoride-containing dentifrice and a soft bristled toothbrush at
their baseline visit.
Subjects may continue to use floss to remove impacted food between the teeth if it is part
of their usual oral care regimen during the course of the study; no other oral hygiene
procedures will be permitted, including teeth cleaning, whitening or dental procedures
except for an emergency treatment. The decision to withdraw a subject due to emergency
dental treatment will occur at the discretion of the Investigator.
At baseline and three weeks (±2 days) visits, subject will not have brushed or have used
their product for at least 8 hours, but no more than 18 hours.
Oral tissue safety, Modified Gingival Index (MGI), Bleeding Index (BI), and Plaque Index
(PI) will be assessed.
;
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator)
Status | Clinical Trial | Phase | |
---|---|---|---|
Not yet recruiting |
NCT05568290 -
Interleukin-38 Levels in Individuals With Periodontitis
|
||
Completed |
NCT04402996 -
Meteorin-like Levels in Individuals With Periodontitis
|
||
Not yet recruiting |
NCT06016023 -
Evaluation of Macrophage Inflammatory Protein-1α as a Periodontal Disease Biomarker
|
||
Not yet recruiting |
NCT05497895 -
The Assessment of Clinical Efficacy of Topical Application of 5% Thymoquinone Gel for Gingivitis Patients
|
Early Phase 1 | |
Completed |
NCT02884817 -
Essential Oil+ELA, Plaque and Gingivitis
|
Phase 4 | |
Completed |
NCT02633345 -
Effects on Tablets Containing Probiotic Candidate Strains
|
N/A | |
Completed |
NCT02552589 -
Effect of Toothpaste on the Reduction of Plaque and Inflammation
|
N/A | |
Unknown status |
NCT01956656 -
Efficacy Of Lotus Leaves In Management Of Plaque Induced Gingivitis
|
N/A | |
Completed |
NCT02515929 -
Prospective Double-Blind Randomized Controlled Clinical Trial in the Gingivitis Prevention With OPCs
|
Phase 4 | |
Completed |
NCT02235532 -
Effects of Aloe Vera Toothpaste on Periodontal Parameters
|
N/A | |
Completed |
NCT02980497 -
Antiplaque/Antigingivitis Efficacy of Essential Oil Mouthrinses in Six-Month Study
|
N/A | |
Completed |
NCT01941797 -
Experimental Peri-implant Mucositis in Humans
|
N/A | |
Completed |
NCT02508987 -
Obesity and Oxidative Stress in Patients With Different Periodontal Status
|
N/A | |
Unknown status |
NCT01197105 -
Evaluation Study of a Mouthwash Based on Schinus Terebinthifolius to Treat Gingivitis in Children
|
Phase 1/Phase 2 | |
Completed |
NCT01593540 -
Clinical Examination of Metal Free Interdental Brushes
|
Phase 4 | |
Completed |
NCT01236963 -
Essential Oils Mouth Rinse and Dental Floss: Efficacy on Interproximal Gingivitis and Dental Plaque Accumulation
|
N/A | |
Completed |
NCT02102295 -
Effects of Antioxidant Dentifrice on Gingivitis
|
Phase 3 | |
Completed |
NCT06140784 -
A Clinical Study to Assess the Gingivitis and Plaque Effects of Various Dentifrices
|
N/A | |
Completed |
NCT02937636 -
To Investigate the Gingivitis Efficacy of a Stannous Fluoride Dentifrice in a Chinese Population
|
N/A | |
Completed |
NCT06212908 -
Assessment of Periodontal Therapy and Biofilm Management in Breast Cancer
|
N/A |